CureVac FDA Briefing Doc 'Reads Consistently' - JMP
By Louis Juricic Shares of CureVac (NASDAQ:CVAC), a biopharmaceutical company developing medicines based on mRNA, climbed 10% early on Thursday after it was upgraded to "Buy" by...
Investing.com - CureVac NV reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. CureVac NV announced earnings...
Oil futures are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However, the news failed to...
Traders await US economic data to justify strongest monthly stock advance in 3 decades Oil rebound slows Bitcoin close to all-time high Key EventsThe most powerful global, monthly...
As the world eagerly awaits results for the U.S. Presidential election, there's yet another highly anticipated event: a breakthrough in the coronavirus vaccine. Positive news about...
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
|Average||17.43 (+161.32% Upside)|
|No. of Analysts||9|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|